Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apollomics Inc. (APLM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Stock Market. Apollomics files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, detailing its clinical-stage oncology business, financial condition, governance changes and material events.
Through these filings, investors can review annual reports on Form 20-F for comprehensive information on Apollomics’ oncology pipeline, including vebreltinib (APL-101) and other disclosed programs, risk factors, financial statements and notes, as well as descriptions of collaborations and licensing arrangements. Interim Form 6-K reports furnish updates on topics such as PIPE financings, reverse share split implementation, auditor changes, Nasdaq listing status, operational continuity plans, and settlements of matters like the Cayman Litigation involving minority investors.
Filings also describe Apollomics’ clinical and strategic decisions, including the conclusion of the uproleselan program after an unfavorable Phase 3 bridging trial in China, termination of the APL-122 development and license agreement with Edison Oncology Holding Corporation, and the company’s focus on advancing vebreltinib through global Phase 2 trials. Disclosures on internal control over financial reporting, changes in independent registered public accounting firms, and remediation of previously identified material weaknesses are available in the same record.
On Stock Titan, Apollomics filings are updated as they are posted to EDGAR, and AI-powered summaries help explain the key points in complex documents. Users can quickly see what each 6-K or 20-F covers, from financial results and impairment charges to listing determinations and settlement agreements, without reading the full text immediately. For those researching APLM, this page is a central resource for understanding how Apollomics presents its oncology strategy, financial performance and corporate governance to regulators and investors.
Apollomics Inc. reported full-year 2025 results showing its first revenue of $8.5M, driven by an upfront payment from the LaunXP licensing deal for vebreltinib in parts of Asia. The company sharply cut operating expenses to $19.8M from $55.7M, reducing its net loss to $10.9M (or $7.57 per diluted share) from $53.9M in 2024.
Cash, cash equivalents, bank deposits and money market funds were $3.3M as of December 31, 2025, down from $9.8M a year earlier, despite raising $4.1M via a PIPE in September 2025. The balance sheet showed a total equity deficit of $3.2M, reflecting accumulated losses. Strategically, Apollomics highlighted global Phase 2 development of its lead c-MET inhibitor vebreltinib, Chinese approvals for vebreltinib and PD-L1 antibody APL-502 in multiple indications, and a 2025 turnaround effort under a new management team with substantial cost reductions and resolution of legacy legal and clinical obligations.
Apollomics Inc. files its annual report highlighting significant going‑concern risks and heavy dependence on a single lead drug. The pre‑revenue oncology company reported a net loss of $10.9 million and operating cash outflows of $10.4 million for the year ended December 31, 2025.
Cash and cash equivalents were $3.3 million at year‑end, plus a $2.3 million receivable from LaunXP and a post‑year‑end $2.0 million unsecured convertible bridge loan from its CEO. Management concludes existing resources are insufficient through April 30, 2027, creating material uncertainty about its ability to continue as a going concern.
The business is "substantially dependent" on vebreltinib. The board deferred a planned U.S. NDA for NSCLC with MET exon 14 skipping after determining the current data package was insufficient and enrollment in a new MET‑amplified cohort has been slow. A separate program, uproleselan, suffered a $10.0 million impairment after negative Phase 3 data from its licensor.
The report details restructuring, headcount reduction to 14 employees, and prior and prospective dilution, including a $4.1 million private placement of 1.04 million Class A Ordinary Shares at $3.9317 per share and the CEO’s note that may convert at a discount in a future financing. The company emphasizes numerous clinical, regulatory, financing, and China‑related operational risks.
Apollomics Inc. director Hong-Jung Chen filed an amended initial ownership report detailing current equity holdings. The filing lists 1,000 restricted stock units, each representing one Class A Ordinary Share, with 500 units vesting on June 15, 2026 and 500 on September 15, 2026. Chen also holds options over 2,290 Class A Ordinary Shares at an exercise price of $75.00 per share and options over 2,028 shares at $6.20 per share, plus warrants over 304 underlying shares at an adjusted exercise price of $1,150.00 per full share. Direct holdings also include 3,120 Class A Ordinary Shares.
Apollomics Inc.'s Chief Financial Officer Peter Kuan-How Lin reported an automatic share disposition related to equity compensation. On the vesting of restricted stock units, 3,582 Class A Ordinary Shares were withheld to cover tax obligations at $15.85 per share. After this tax-withholding event, Lin directly holds 12,318 Class A Ordinary Shares. This was not an open-market sale but a routine mechanism tied to RSU vesting.
Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report showing equity awards and share holdings. The filing lists 1,000 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. These RSUs are scheduled to vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also reports direct ownership of 1,000 Class A Ordinary Shares following the reported positions.
Apollomics Inc. director Tsai Hsien-Shu reports equity holdings consisting of restricted stock units and common shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.00 per share.
These restricted stock units will vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also lists direct ownership of 1,000 Class A Ordinary Shares following the reported holdings.
Apollomics Inc. Chief Financial Officer LIN PETER KUAN-HOW reported his equity holdings in an amended Form 3. He holds restricted stock units representing 20,000 Class A Ordinary Shares and 15,900 Class A Ordinary Shares directly. The restricted stock units will vest in two equal installments of 10,000 shares each on June 15, 2026 and September 15, 2026.
Apollomics Inc. director and CEO Chen Hung-Wen has updated his reported equity holdings. The filing shows direct ownership of 143,334 Class A Ordinary Shares and indirect ownership of 763,028 Class A Ordinary Shares through King Regent Management Limited, where he is the sole director and shareholder and has voting and dispositive power.
He also holds Restricted Stock Units representing a contingent right to receive 10,000 Class A Ordinary Shares at an exercise price of $0.0000 per share. These RSUs are scheduled to vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. Mr. Chen disclaims beneficial ownership of the securities held by King Regent Management Limited except to the extent of his pecuniary interest.
Apollomics Inc. director CHU YI-AN reports equity holdings consisting of restricted stock units and related Class A Ordinary Shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.0000 per share.
According to the disclosure, these restricted stock units are scheduled to vest with respect to 500 shares on June 15, 2026 and 500 shares on September 15, 2026. Following this reporting, the position includes 1,000 Class A Ordinary Shares tied to this award, all held as direct ownership.
Apollomics Inc. chief operating officer Chen Yi-Kuei filed an amended initial ownership report detailing his equity interests. He directly holds 10,000 Class A Ordinary Shares and 10,000 restricted stock units, each representing a right to one Class A Ordinary Share. The restricted stock units will vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. In addition, entities associated with him, including Maxpro Investment Co., Ltd., hold 101,248 Class A Ordinary Shares and warrants linked to 3,823 underlying Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, and he disclaims beneficial ownership except to the extent of his pecuniary interest.